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ABSTRACT  Most of the proposed functions for fibronectin  involve its interaction with cells, yet the 
molecular  nature of cellular  fibronectin  binding  site(s) has remained  obscure. Thrombin  induces 
saturable platelet binding sites for plasma fibronectin  and concurrently stimulates surface expression 
of a number of platelet a-granule constituents including thrombospondin  and fibrin which are known 
to interact with fibronectin.  To test the hypothesis that these (or other a-granule proteins) mediate 
plasma fibronectin  binding,  we  used platelets of patients with the Gray Platelet Syndrome. These 
cells  were  deficient  in  thrombospondin,  /3-thromboglobulin,  platelet  factor  4,  fibronectin,  and 
fibrinogen as measured in radioimmunoassay. They also had reduced von Willebrand  factor content 
as judged  by immunofluorescence.  At plasma fibronectin  inputs from 0.03 to3 times the apparent 
kilodalton,  these Gray platelets bound virtually  identical  quantities of fibronectin  as normal cells. 
Thus, platelets containing  1,500 molecules of thrombospondin  per platelet could bind  more than 
100,000 molecules of plasma fibronectin per cell following thrombin stimulation. These data preclude 
any simple model  in which newly surface expressed thrombospondin  (or other a-granule protein) 
functions as the major thrombin-stimulated  plasma fibronectin  receptor in this cell type. 
Fibronectins have been implicated in a  number of cellular 
interactions including  adhesion  to  fibrin  and  to  collagen, 
opsonization, and in the regulation of cell migration (1, 2). 
Each of these potential functions of fibronectin requires that 
it bind  to cell surfaces.  Although  both glycolipids (3) and 
protein constituents (4) have been implicated as cellular fibro- 
nectin "receptors" the molecular identity of such "receptors" 
has remained obscure. We recently described inducible, spe- 
cific, and saturable binding of soluble plasma fibronectin to 
thrombin-stimulated platelets. This interaction has an appar- 
ent dissociation constant of 3 x  10  -7 M  (5), approximately 
half the  normal  plasma  fibronectin concentration (1),  and 
120,000 molecules per platelet are bound at saturation. 
While thrombin supports this interaction, ADP and epi- 
nephrine,  which  do  not  induce  secretion under our assay 
conditions, failed to support plasma fibronectin binding (5). 
In addition to secretion, thrombin also stimulates appearance 
of  certain constituents of  platelet a-granules on the cell surface 
(6-9). Thus, the possibility that a newly surface expressed a- 
granule constituent mediates plasma fibronectin attachment 
to thrombin-stimulated platelets merits consideration. 
One candidate a-granule protein is platelet fibrinogen, or 
platelet fibrin, which is present at a level of approximately 
100,000  molecules per platelet and is expressed on the cell 
surface following thrombin stimulation (8). Moreover, fibrin- 
ogen and fibrin interact with fibronectin, although the non- 
covalent interaction is of low affinity at 37°C (10). Neverthe- 
less, platelet fibrinogen or fibrin appears unlikely to serve such 
a role, since we recently found that platelets from afibrinoge- 
nemic patients,  containing <2%  of the  normal  fibrinogen 
content, bind plasma fibronectin normally (11). 
A second candidate, a-granule protein for such a function 
is thrombospondin (TSP).  This protein,  purified in  native 
form by Lawler et al. (12), is a trimer of 150-kdalton subunits 
and approximately 40,000 molecules are present per platelet 
(13).  Thus,  120,000  molecules of TSP subunit per platelet 
could accommodate fibronectin binding, in a  1:1 stoichiom- 
etry. TSP is expressed on the surface of thrombin-stimulated 
cells (6), and has been reported to bind both fibrinogen and 
fibronectin (14). Moreover, since TSP is synthesized by fibro- 
blasts (15), endothelial cells ( 16, 17), and smooth muscle cells 
(15), and appears to be a matrix protein (15), it might support 
fibronectin interactions with cells other than platelets.  Recent 
studies of Lahav et al. (18) have shown that when fibronectin 
derivatized with N-succinimidyl-3-[2-(nitro-4-azidophenyl)-2- 
aminoethyldithio] proprionate is reacted with adherent plate- 
lets, photoactivation results in cross-linking to thrombospon- 
din. Thus, TSP might serve as the newly expressed plasma 
fibronectin receptor on thrombin-stimulated platelets. 
The Gray Platelet Syndrome is a mild bleeding diathesis in 
which  platelets have a  markedly reduced content of alpha 
granules  (19)  and  are  deficient in  a  variety of a-granule 
proteins, including fibrinogen, platelet factor 4, ~-thrombo- 
globulin (19),  fibronectin, and  von Willebrand  factor (20). 
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TSP on SDS PAGE (19). Our investigation's purpose was to 
test the potential role of TSP (or other a-granule proteins) in 
the  binding  of plasma  fibronectin to  thrombin-stimulated 
platelets by analysis of its interaction with platelets of  patients 
with the Gray Platelet Syndrome. 
MATERIALS  AND  METHODS 
Patients:  The two patients with Gray Platelet  Syndrome are unrelated 
individuals who are followed  at the University of Minnesota and have been 
extensively characterized in published literature (19). Their platelets have been 
reported  to  have <10%  of the normal content of a-granules as assayed by 
morphometric techniques, and <10% of the normal content of platelet factor 
4,/~-thromboglobulin, and fibrinogen (19). 
Platelet Isolation and  Binding Assays:  Anti-coagulated blood 
from the gray platelet patients and normals were  simultaneously obtained in 
acid citrate dextrose anticoagulant at the University of Minnesota. Platelet-rich 
plasma was isolated  by differential centrifugation as described (5),  and the 
platelet-rich  plasma was shipped Air Freight  to  San  Diego,  where  washed 
platelets were prepared and studied within l0 h of venipuncture. The technique 
of platelet  washing has been described in  detail  (5).  Briefly,  platelet  pellets 
obtained by centrifugation of platelet-rich  plasma, were resuspended in 2 ml of 
modified Tyrode's buffer, pH 6.5, containing 2 mM MgCl2 and 0. 1% BSA, and 
gel filtered  on the column (2.5  x  l0 cm) to Sepharose 2B equilibrated in the 
modified Tyrode's buffer at pH 7.4. In binding assays, l0  s platelets per milliliter 
were incubated in the presence of 2 U/ml purified human a-thrombin (gift of 
Dr. John Fenton, New York State Department of Health) and of various doses 
of ~251-labeled  fibronectin (purification and radiolabeling described in reference 
5) for 30 min at 37"C, and triplicate 50-ul aliquots were layered onto 200 ~l of 
20%  sucrose in  modified Tyrode's buffers and centrifuged for  3  min in a 
Beckman microfuge B (Beckman Instruments, Inc., Palo Alto, CA). Tips were 
amputated and counted, and the fibronectin bound was calculated from the 
specific activity of ligand using a molecular weight of 440,000. 
Radioimmonoassay:  109 platelets per milliliter  were lysed in a buffer 
containing 1%  Triton X-100, snap frozen, and stored in aliquots at -70"C. 
Each aliquot was thawed only once prior to analysis. Radioimmunoassays  for 
platelet  factor 4 (21), fibrinogen (22), and fibronectin (23) have been described 
in detail previously. Radioimmunoassay for/~-thromboglobulin employed an- 
tibody and antigen generously  provided by Dr. Duncan S. Pepper of  the Scottish 
Transfusion Service,  Edinburgh, U.K. It was radiolabeled,  and the assay was 
performed  using ammonium sulfate precipitation  employing the  identical 
buffers used in the platelet factor 4  assay (21).  The radioimmunoassay for 
thrombospondin has been described in detail elsewhere (U. Marzec, L. Harker, 
and M. Ginsberg, manuscript in preparation). Briefly, human TSP was purified 
from a  releasate  of thrombin-stimulated platelets by a  modification of the 
procedure of Lawler et al. (12), the purified antigen was >95% homogeneous 
as judged by  PAGE  in  the presence of SDS.  It  was radiolabeled  with  1251 
employing chloramine T oxidation to a specific activity of I ~Ci/t~g. Anti-TSP 
was raised in rabbits, and the antibody was detected by its ability to bind ~251- 
TSP in the radioimmunoassay. This antibody was characterized as immuno- 
precipitating only TSP from radiolabeled  platelet lysates and did not bind to 
flbronectin or fibrinogen in their radioimmunoassays. The TSP radioimmu- 
noassay was performed using buffer systems described for the platelet factor 4 
radioimmunoassay (2 l)  and a  double antibody immunoprecipiation. Assay 
sensitivity was ~  1 ng of TSP/ml and was not influenced by the presence of 
TABLE  I 
Content of a-Granule Proteins in Normal and Gray Platelets 
Normal platelet  Gray Platelet 
content  content 
(~g/109 platelets)  (~g/| 09 platelets) 
TSP  24.6  1.0 
Fibrinogen  88.3  6.5 
Fibronectin  2.5  0.6 
Platelet factor 4  9.5  0.5 
B-TSP  18.0  0.7 
I% Triton-X-100  lysates, derived from  platelet suspensions containing 109 
platelets per milliliter, were assayed for each protein in radioimmunoassays 
as described  in Materials and Methods. Results are the means of determina- 
tions  on two different Gray  Platelet  patients and  simultaneously  prepared 
and assayed normal subjects. 
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plasma, platelet  lysates, or heparin (U. Marzec, L. Harker, and M. Ginsberg, 
manuscript in preparation). 
Immunofluorescent  Staining:  Immunofluoreseence  protocols 
have been published in detail elsewhere  (24).  Briefly, platelets were  fixed  in 
suspension with 2% paraformaldehyde for l h in melting ice. The paraformal- 
dehyde was neutralized with 20 mM ammonium chloride in l0 mM Tris, 150 
mM NaC1, pH 7.4, and the cells were washed in  l0 mM Tris 150 mM NaCl, 
pH 7.4,  and permitted to settle onto polylysine-coated cover slips, Following 
this, they were permeabilized by 3-min treatment in 0.1% Triton X-100, and 
stained using rabbit anti-TSP, anti-~-thromboglobulin, and anti-platelet factor 
4, anti-von Willebrand factor,  or antifibronectin, followed  by fluoresceinated 
goat anti-rabbit immunogiobulin and rhodaminated goat anti-human fibrino- 
gen. The characterization of all the primary antibodies is reported elsewhere 
(25),  as  are  the  filter  systems employed.  Results were  recorded  on  Tfi-X 
panchromatic film. 
RESULTS AND  DISCUSSION 
Reduction of c~-Granule Constituents in 
Gray Platelets 
To confirm that the platelets of the two patients studied 
were deficient in the relevant proteins at the time of study, 
lysates of  their cells were analyzed by radioimmunoassay. The 
gray platelets were profoundly deficient in TSP, platelet factor 
4, and/3-thromboglobulin (content ~5% of normals) (Table 
I).  Fibrinogen and  fibronectin were also  reduced but  to  a 
lesser degree (10% and 25% of normal, respectively).  Since 
plasma fibrinogen (gray =  1,850 ~g/ml; normal =  2,500 #g/ 
ml) and fibronectin (gray = 418/~g/ml; normal = 418 ~g/ml) 
were not reduced in the gray platelet patients, the comparative 
abundance 0fthese proteins in gray platelet lysate may be due 
to plasma contamination. In any event, with respect to TSP, 
the gray platelets contained an average of 1,500 molecules per 
platelet, indicating reduced content of this protein. 
We considered the possibility that TSP antigen (or other 
proteins) was destroyed in the gray platelets during lysis. To 
test this, we performed immunofluorescence analysis of the 
FIGURE  I  Reduced immunofluorescent staining for fibrinogen and 
yon  Willebrand  Factor  in  gray  platelets.  Platelets  were  double 
stained for fibrinogen  and  von Willebrand  Factor as described  in 
Materials and Methods. The left panels illustrate fibrinogen staining 
and the right illustrate yon Willebrand  Factor staining. The normal 
cells are depicted in the upper panel and the gray platelets below. 
x  1,600. unextracted cells and confirmed the defciency  of TSP and 
other a-granular proteins in  the gray  cells (not shown).  In 
addition, the gray platelets did not stain for Factor VIII von 
Willebrand factor (Fig.  1). 
Binding of Plasma Fibronectin to Thrombin- 
stimulated Gray Platelets 
To evaluate their ability to bind plasma fibronectin, the 
gray platelets were incubated with various doses of z25I-fibro- 
nectin in  the presence of 2  U  of thrombin/ml, and bound 
ligand was separated from free by centrifugation through 20% 
sucrose. TSP-deficient platelets and normal platelets bound 
virtually identical quantities of fibronectin at input doses from 
0.03 to 3 times the apparent kilodalton, 3 ×  10 -7 M (5) (Fig. 
2). 
Thus, platelets containing <5 % of the normal TSP content 
bound plasma fibronectin as well as normal cells. This result 
suggests  that  if  TSP  participates  in  thrombin-stimulated 
plasma fibronectin binding, it is normally present in at least 
20-fold  excess  of the  quantity  required  for  this  function. 
Secondly, since platelets containing only  1,500 molecules of 
TSP per platelet could bind more than 100,000 molecules of 
plasma  fibronectin  per  platelet,  TSP  must  not  be  binding 
fibronectin to the platelet surface in a one-to-one stoichiom- 
etry.  These data thus preclude any simple  model in which 
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FIGURE 2  Binding of plasma fibronectin to normal and gray plate- 
lets. 12Sl-fibronectin at the indicated input concentrations was in- 
cubated at  370C  with  108  platelets/ml in  the  presence  of 2  U 
thrombin/ml for 30 rain.  Under conditions which inhibit TSP re- 
binding, similar doses of thrombin induce secretion of virtually all 
platelet thrombospondin (8). Binding was measured as described 
in Materials and Methods. (0) Normal. (O) Gray platelets. Means of 
triplicate determinations on two different Gray Platelet patients and 
two simultaneously assayed normals. 
surface expression  of TSP  accounts for plasma  fibronectin 
binding to suspensions of thrombin-stimulated platelets. 
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